[Lab] TFC cagri — Janoshik came back 98.1% against a claimed 98.0%
Filing this under things worth writing down: TFC cagri — Janoshik came back 98.1% against a claimed 98.0%.
Since the title puts numbers in the shop window: 98.1% and 98.0%.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
Ask me anything specific. Anything general I will probably get wrong.
- TFTFC source pageTianjin Finder Chemical Co., Ltd. · Tianjin · 98% here, rank 1 · shop at tfcpeptides.com →
nofollow and sponsored; nobody here is paid for it.best — the order this archive was captured in
Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.
Is there any independent purity data on this compound that you have seen?
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
What does the tolerability table in that paper actually say?
Sent a vial to VendorInvestigate because there was almost nothing on file for this compound. 97.6% against a claimed 97.0%, and I posted it because the log needs entries.
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
long-acting amylin is the whole point of the molecule
Correcting myself upthread: I gave the 92-week figure and the paper reports 43 weeks.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes.
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
this is a less-travelled board and the evidence base shows it
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Combination and monotherapy arms must be read separately.
nl_verzekering is right that the evidence base here is thin. Conclusions should be held loosely.
do not assume the dosing intuitions from the GLP-1 boards transfer
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
- 1Standing reminder: nothing here is approved standalone, research material is…6 comments in this branch · started by u/amylin_amy
- 2Amylin is co-secreted with insulin and acts on satiety and gastric emptying…6 comments in this branch · started by u/lukas_vermeulen